Boxplots representing variations between pre-, post- and 24h-post training sessions, for the salivary measures, in the first (above) and second (below) half. by Davide Curzi (466778)

Subjects:

Schematic of main kennel area. by Grace Hecker (18813445)

Subjects:

Descriptive statistics (median [first-third quartile]) grouped by Half (first vs second half) and Time (pre-, post- and 24h post-training). by Davide Curzi (466778)

Subjects:

Significant changes in taxa at discharge. by Arnon Gal (3150036)

Quantification of intensity changes in the contrast generated by Gd in T1 imaging. by Juan F. Zapata-Acevedo (18349423)

Subjects:

Significant changes in taxa at 30 days. by Arnon Gal (3150036)

CRISPRi knockdown of RgaR-dependent genes specifically and significantly decreases their transcript levels. by Adrianne N. Edwards (5646344)

Significant cohort differences pre-post intervention. by Kerstin Meints (324567)

Significant main effect of age showing decreased gray matter volume in nearly the entire cortical brain and subcortical cortex. by Zhiliang Long (306092)

Bexarotene pretreatment significantly suppressed HBV and HDV infections in primary human hepatocytes (PHH). by Sameh A. Gad (12269979)

“…<b>(B)</b> HBsAg secreted into the culture supernatant was quantified by ELISA, and the data were presented as fold changes relative to the values of control DMSO-pretreated cells. …”

Significant changes in taxa at admission (AHDS vs donors). by Arnon Gal (3150036)

Significant changes in whole-brain voxelwise analysis. by José V. Pardo (8293983)

CLDT Metabolomics Table S3. Significant changes in metabolites from pre- to post-CLDT by Meaghan Beckner (11436547)

“…<p>Supplemental Table 3. Significant changes in the serum metabolome during Cadet Leader Development Training (CLDT). …”

Gardner-Altman estimation plots identifying Pre- and Post-intervention individual changes for jump momentum and Hedge’s g effect size with the 95% CI indicated by the ends of the v... by Nicholas J. Ripley (14709756)

Subjects:

The body composition changes for individual participants post- to post-expedition. by John Hattersley (7252400)

USPIO as MRI contrast agent. by Juan F. Zapata-Acevedo (18349423)

Subjects:

Reagents and antibodies. by Juan F. Zapata-Acevedo (18349423)

Subjects:

Representative in vivo T2*-weighted MRI images of control mice and mice with EAE before and after NPS-P88 injection. by Juan F. Zapata-Acevedo (18349423)

Subjects:

Representative in vivo T1-weighted MRI images of control mice and mice with EAE before and after gadolinium (Gd). by Juan F. Zapata-Acevedo (18349423)

Subjects:

Representative in vivo T1, T2* and merge-weighted MRI images of control mice and mice with EAE before and after gadolinium (Gd) and NPS-P88. by Juan F. Zapata-Acevedo (18349423)

Subjects: